Compare AbCellera Biologics Inc (ABCL) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Krispy Kreme Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Krispy Kreme Inc trades at $3.48 (market cap $572.37M). The key difference: AbCellera Biologics Inc is far larger — about 4.1× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DNUT | |
|---|---|---|
Market Cap | $2.35B | $572.37M |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $4.70 |
52-Week Low | $2.78 | $2.92 |
Enterprise Value | $1.99B | $1.77B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Krispy Kreme (DNUT) trades at $3.32, down 5.41% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of -$0.05, missing expectations, though Q4 2025 and Q3 2025 beat estimates. Revenue for 2025 was $1.52B with a net loss of -$515.77M, reflecting a -33.36% net margin. Analyst consensus is 50% buy, 35.71% hold, and 14.29% sell. Recent news highlights automation efforts and new product launches to attract younger consumers.
The outlook remains challenging with persistent losses and high debt, but strategic pivots to capital-light models and international growth offer potential. Risks include execution missteps and competitive pressures. Investors should weigh turnaround progress against financial instability, with Q2 2026 earnings on August 6, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
